MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with...
SPY - did not make a higher high the entire day as sellers were firmly in control. Opening in the PM at the key 400 level. With the VIX finally spiking yesterday and bond prices making new lows., it appears like the price action and market internals indicate this short term bear action will continue. We would need to hear dovish comments from Bullard's speak at...
Going from a strong bear market shown with the red dotted line
To a recent bull market development shown with the vertical green line and triangle structure
MNKD has been consolidating for want seems to be forever, but since April of 2020 it's been catching a little bit of a pump which peaked sometime in March of this year. Since then it has created a symmetrical triangle. On its own a symmetrical triangle does not mean much, but if we look at other indicators like the weekly 200 MA, together with the RSI and the...
MNKD is back at a frequent level of "traffic" this week. After doing a quick retracement we can see that the 618 area continues to act as a magnate a key pivot area. After bouncing off this last time, MNKD has continued higher on a decent multi-day move. Now, moving forward, a fundamental focus could be on what happens with its next potential commercial product,...
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI(TM) With New Drug Application Acceptance From The FDA. Mannkind's insulin inhaler Alfrezza since approval 7 years ago has not been a game changer for the company's revenue and bottom line although has marginally increase on monthly and yearly basics, the recent news I...
Wave#2
Monthly SMA12/24 as support
Monthly OBV > OBV Avg24
Entry 4.15
Stop 2
Target 11
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SIM/Demo account to try it.
MNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption?
" However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza...
"Mannkind Corp" has broken above a previous resistance area with a strong price gain supported by greater than normal volume . Be careful as it could pull back. Perhaps look for a buy price if it reaches 6.30$ to confirm direction"
1% maximum size of your portofolio
